Abstract
Backgrounds/Aims
Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. Methods: Ninety-seven patients were treated with peginterferon alpha-2a (180 ?g/week, n=48) or peginterferon alpha-2b(1.5 ?g/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. Results: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peg-interferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. Conclusions: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients. (Korean J Hepatol 2008;14:493-502)
Citations
Citations to this article as recorded by
- Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
Hyun Seok Lee, Young Oh Kweon, Won Young Tak, Soo Young Park, Eun Jung Kang, Yu Lim Lee, Hae Min Yang, Hyun Woo Park
Clinical and Molecular Hepatology.2013; 19(2): 148. CrossRef - Role of Interleukin 28B-related Gene Polymorphisms in Chronic Hepatitis C and the Response to Antiviral Therapy in Koreans
Young Kul Jung, Ji Hoon Kim, Sung-Min Ahn, Jae Won Yang, Sang Jin Park, Jong Woo Kim, Jong Eun Yeon, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim, Kwan Soo Byun
Journal of Clinical Gastroenterology.2013; 47(7): 644. CrossRef - Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C
Nicolas Flori, Natalie Funakoshi, Yohan Duny, Jean-Christophe Valats, Michael Bismuth, Dimitri Christophorou, Jean-Pierre Daurès, Pierre Blanc
Drugs.2013; 73(3): 263. CrossRef - Efficacy of Peginterferon and Ribavirin Combination Therapy of Chronic Hepatitis C: A Pooled Analysis
Soo Yong Park, Min Young Rim, In Ku Yo, Min Su Ha, Ju Seung Kim, Ji Won Lee, Young Kul Jung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
The Korean Journal of Gastroenterology.2012; 60(5): 306. CrossRef - Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
Seok Hoo Jeong, Young Kul Jung, Jae Won Yang, Sang Jin Park, Jong Woo Kim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Clinical and Molecular Hepatology.2012; 18(4): 360. CrossRef - Recent trends in the treatment of chronic hepatitis C
Dae Won Jun, Won Young Tak, Si Hyun Bae, Youn Jae Lee
The Korean Journal of Hepatology.2012; 18(1): 22. CrossRef - Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh
The Korean Journal of Hepatology.2011; 17(3): 220. CrossRef - Current status of liver disease in Korea: Hepatitis C
Young-Suk Lim
The Korean Journal of Hepatology.2009; 15(Suppl 6): S25. CrossRef - Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
Youn Jae Lee
The Korean Journal of Hepatology.2008; 14(4): 443. CrossRef
